SARS-CoV-2 Disease Adjuvant Therapies and Supplements Breakthrough for the Infection Prevention

被引:62
|
作者
Inchingolo, Alessio Danilo [1 ]
Inchingolo, Angelo Michele [1 ]
Bordea, Ioana Roxana [2 ]
Malcangi, Giuseppina [1 ]
Xhajanka, Edit [3 ]
Scarano, Antonio [4 ]
Lorusso, Felice [4 ]
Farronato, Marco [5 ]
Tartaglia, Gianluca Martino [5 ]
Isacco, Ciro Gargiulo [1 ,6 ,7 ]
Marinelli, Grazia [1 ]
D'Oria, Maria Teresa [1 ,8 ]
Hazballa, Denisa [1 ,9 ]
Santacroce, Luigi [1 ]
Ballini, Andrea [10 ,11 ]
Contaldo, Maria [12 ]
Inchingolo, Francesco [1 ]
Dipalma, Gianna [1 ]
机构
[1] Univ Med Aldo Moro, Dept Interdisciplinary Med, I-70124 Bari, Italy
[2] Iuliu Hatieganu Univ Med & Pharm, Dept Oral Rehabil, Fac Dent, Cluj Napoca 400012, Romania
[3] Med Univ Tirana, Dent Prosthesis Dept, UMT, Tirana 1001, Albania
[4] Univ G dAnnunzio, Dept Innovat Technol Med & Dent, I-66100 Chieti, Italy
[5] Univ Milan, UOC Maxillofacial Surg & Dent, Dept Biomed Surg & Dent Sci, Sch Dent,Fdn IRCCS Ca Granda,Osped Maggiore Polic, I-20100 Milan, Italy
[6] Human Stem Cells Res Ctr HSC Ho Chi Minh, Ho Chi Minh City 70000, Vietnam
[7] Pham Chau Trinh Univ Med Hoi An, Embryol & Regenerat Med & Immunol, Hoi An 70000, Vietnam
[8] Univ Udine, Dept Med & Biol Sci, Via Sci 206, I-33100 Udine, Italy
[9] Kongresi Elbasanit, Rruga Aqif Pasha, Elbasan, Albania
[10] Univ Bari, Dept Biosci Biotechnol & Biopharmaceut, Campus Univ, I-70125 Bari, Italy
[11] Univ Campania, Dept Precis Med, I-80138 Naples, Italy
[12] Univ Campania Luigi Vanvitelli, Multidisciplinary Dept Med Surg & Dent Specialtie, Via Luigi de Crecchio 6, I-80138 Naples, Italy
关键词
SARS-CoV-2; COVID-19; pandemics; resveratrol; oral mucosa; furin; cytokine storm syndrome; microbiome; vaccines; endovir stop spray; RICH FIBRIN PRF; CYSTIC-FIBROSIS; SPIKE PROTEIN; CORONAVIRUS INFECTIONS; PERIODONTAL-DISEASE; COVID-19; PATIENTS; CYTOKINE STORM; GROWTH-FACTORS; PLASMA PRP; STEM-CELLS;
D O I
10.3390/microorganisms9030525
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is a high-risk viral agent involved in the recent pandemic stated worldwide by the World Health Organization. The infection is correlated to a severe systemic and respiratory disease in many cases, which is clinically treated with a multi-drug pharmacological approach. The purpose of this investigation was to evaluate through a literature overview the effect of adjuvant therapies and supplements for the SARS-CoV-2 infection. The research has analyzed the advantage of the EK1C4, by also assessing the studies on the resveratrol, vitamin D, and melatonin as adjuvant supplements for long hauler patients' prognosis. The evaluated substances reported important benefits for the improvement of the immune system and as a potential inhibitor molecules against SARS-CoV-2, highlighting the use of sartans as therapy. The adjuvant supplements seem to create an advantage for the healing of the long hauler patients affected by chronic symptoms of constant chest and heart pain, intestinal disorders, headache, difficulty concentrating, memory loss, and tachycardia.
引用
收藏
页码:1 / 28
页数:28
相关论文
共 50 条
  • [1] Cellular therapies for the treatment and prevention of SARS-CoV-2 infection
    Conway, Susan R.
    Keller, Michael D.
    Bollard, Catherine M.
    [J]. BLOOD, 2022, 140 (03) : 208 - 221
  • [2] Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies
    Schiavetti, Irene
    Cordioli, Cinzia
    Stromillo, Maria Laura
    Ferro, Maria Teresa
    Laroni, Alice
    Cocco, Eleonora
    Cola, Gaia
    Pasquali, Livia
    Rilla, Maria Teresa
    Signoriello, Elisabetta
    Iodice, Rosa
    Di Sapio, Alessia
    Lanzillo, Roberta
    Caleri, Francesca
    Annovazzi, Pietro
    Conte, Antonella
    Liberatore, Giuseppe
    Ruscica, Francesca
    Docimo, Renato
    Bonavita, Simona
    Ulivelli, Monica
    Cavalla, Paola
    Patti, Francesco
    Ferraro, Diana
    Clerico, Marinella
    Immovilli, Paolo
    Di Filippo, Massimiliano
    Salvetti, Marco
    Sormani, Maria Pia
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (13) : 2106 - 2111
  • [3] What should define a SARS-CoV-2 "breakthrough" infection?
    Schieffelin, John S.
    Norton, Elizabeth B.
    Kolls, Jay K.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2021, 131 (12):
  • [4] Long COVID after breakthrough SARS-CoV-2 infection
    Al-Aly, Ziyad
    Bowe, Benjamin
    Xie, Yan
    [J]. NATURE REVIEWS IMMUNOLOGY, 2022, 22 (07) : 410 - 410
  • [5] Long COVID after breakthrough SARS-CoV-2 infection
    Ziyad Al-Aly
    Benjamin Bowe
    Yan Xie
    [J]. Nature Medicine, 2022, 28 (7) : 1461 - 1467
  • [6] Panorama of Breakthrough Infection Caused by SARS-CoV-2: A Review
    Fan, Qinglu
    Nie, Zhihao
    Xie, Songping
    [J]. MEDICINA-LITHUANIA, 2022, 58 (12):
  • [7] Long COVID after breakthrough SARS-CoV-2 infection
    Al-Aly, Ziyad
    Bowe, Benjamin
    Xie, Yan
    [J]. NATURE MEDICINE, 2022, 28 (07) : 1461 - +
  • [8] Predictors of Breakthrough SARS-CoV-2 Infection after Vaccination
    Walmsley, Sharon
    Nabipoor, Majid
    Lovblom, Leif Erik
    Ravindran, Rizani
    Colwill, Karen
    Mcgeer, Alison
    Dayam, Roya Monica
    Manase, Dorin
    Gingras, Anne-Claude
    [J]. VACCINES, 2024, 12 (01)
  • [9] Practical measures for SARS-CoV-2 infection prevention
    Fujikawa, Tatsuya
    [J]. LANCET INFECTIOUS DISEASES, 2022, 22 (01): : 20 - 21
  • [10] Primary and Recall Immune Responses to SARS-CoV-2 in Breakthrough Infection
    D'Orso, Silvia
    Pirronello, Marta
    Verdiani, Alice
    Rossini, Angelo
    Guerrera, Gisella
    Picozza, Mario
    Sambucci, Manolo
    Misiti, Andrea
    De Marco, Lorenzo
    Salvia, Antonino
    Caltagirone, Carlo
    Giardina, Emiliano
    Battistini, Luca
    Borsellino, Giovanna
    [J]. VACCINES, 2023, 11 (11)